Phase II study of a biweekly schedule of docetaxel and cisplatin in patients with metastatic non-small cell lung cancer

Lung Cancer

Volumn 69, Issue 1, 2010, Pages 94-98

  Cho, Su Hee ^a,b,c   Go, Se Il ^a,b,c   Lee, Gyeong Won ^a,b,c   Kang, Jung Hun ^a,b,c   Kim, Hoon Gu ^a,b,c   Kim, Seok Hyun ^a   Cho, Yu Ji ^a,b   Jeong, Yi Yeong ^a,b,c   Kim, Ho Cheol ^a,b,c   Lee, Jong Duk ^a,b,c   Hwang, Young Sil ^a,b,c  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Gyeongsang National University   (South Korea)

^c Gyeongnam Regional Cardiocerebrovascular Disease Center   (South Korea)

Author keywords

Biweekly administration; Cisplatin; Docetaxel; Non small cell lung cancer

Indexed keywords

CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PEMETREXED; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEUROPATHY; NEUTROPENIA; OUTPATIENT CARE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; INFECTION; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUTROPENIA; SURVIVAL ANALYSIS; TAXOIDS;

EID: 77953362013     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.09.005     Document Type: Article

References (38)

1. Bae J.M., Won Y.J., Jung K.W., Park J.G. Annual Report of the Korea Central Cancer Registry Program 2000: based on registered data from 131 hospitals. Cancer Res Treat 2002, 34:77-83.
2. Cappuzzo F., Novello S., De Marinis F., Franciosi V., Maur M., Ceribelli A., et al. Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer 2005, 93:29-34.
3. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
4. Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001, 37:S4-S66.
5. Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2000, 2:CD002139. Non-small Cell Lung Cancer Collaborative Group.
6. Bunn P.A., Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998, 4:1087-1100.
7. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., et al. American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.
8. Cerny T., Kaplan S., Pavlidis N., Schöffski P., Epelbaum R., van Meerbeek J., et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 1994, 70:384-387.
9. Francis P.A., Rigas J.R., Kris M.G., Pisters K.M., Orazem J.P., Woolley K.J., et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994, 12:1232-1237.
10. Fossella F.V., Lee J.S., Murphy W.K., Lippman S.M., Calayag M., Pang A., et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994, 12:1238-1244.
11. Fossella F.V., Lee J.S., Shin D.M., Calayag M., Huber M., Perez-Soler R., et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995, 13:645-651.
12. Gandara D.R., Vokes E., Green M., Bonomi P., Devore R., Comis R., et al. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 2000, 18:131-135.
13. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000, 18:2354-2362.
14. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
15. Kunitoh H., Watanabe K., Onoshi T., Furuse K., Niitani H., Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol 1996, 14:1649-1655.
16. Hainsworth J.D., Burris H.A., Erland J.B., Thomas M., Greco F.A. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998, 16:2164-2168.
17. Briasoulis E., Karavasilis V., Anastasopoulos D., Tzamakou E., Fountzilas G., Rammou D., et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999, 10:701-706.
18. Greco F.A. Docetaxel (Taxotere) administered in weekly schedules. Semin Oncol 1999, 26:28-31.
19. Lai C.L., Tsai C.M., Chiu C.H., Wang G.S., Su W.J., Chen Y.M., et al. Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. Jpn J Clin Oncol 2005, 35:700-706.
20. Park S.H., Choi S.J., Kyung S.Y., An C.H., Lee S.P., Park J.W., et al. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer. Cancer 2007, 109:732-740.
21. Schuette W., Nagel S., Blankenburg T., Lautenschlaeger C., Hans K., Schmidt E.W., et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005, 23:8389-8395.
22. Camps C., Massuti B., Jiménez A., Maestu I., Gómez R.G., Isla D., et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006, 17:467-472.
23. Gervais R., Ducolone A., Breton J.L., Braun D., Lebeau B., Vaylet F., et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005, 16:90-96.
24. Chen Y.M., Shih J.F., Perng R.P., Tsai C.M., Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006, 129:1031-1038.
25. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
26. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
27. Goh B.C., Lehnert M., Lim H.L., Ng A.W., Chan C.C., Kong H.L., et al. Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer. Acta Oncol 2000, 39:225-229.
28. Miyata M., Yasuda K., Burioka N., Takane H., Suyama H., Shigeoka Y., et al. The influence of granisetron on the pharmacokinetics and pharmacodynamics of docetaxel in Asian lung cancer patients. Cancer J 2006, 12:69-72.
29. Goh B.C., Lee S.C., Wang L.Z., Fan L., Guo J.Y., Lamba J., et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002, 20:3683-3690.
30. Bosch T.M., Huitema A.D., Doodeman V.D., Jansen R., Witteveen E., Smit W.M., et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 2006, 12:5786-5793.
31. Gridelli C., Gallo C., Di Maio M., Barletta E., Illiano A., Maione P., et al. A randomised clinical trial of two docetaxel regimens (weekly vs. 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004, 91:1996-2004.
32. Di Maio M., Perrone F., Chiodini P., Gallo C., Camps C., Schuette W., et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007, 25:1377-1382.
33. Iwasaki Y., Ohsugi S., Natsuhara A., Tsubokura T., Harada H., Ueda M., et al. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer. Cancer Chemother Pharmacol 2006, 58:735-741.
34. Frasci G., Comella P., Thomas R., Di Bonito M., Lapenta L., Capasso I., et al. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study. Cancer Chemother Pharmacol 2004, 53:25-32.
35. Frasci G., D'Aiuto G., Thomas R., Comella P., Di Bonito M., Lapenta L., et al. Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients. Oncology 2005, 68:391-397.
36. Al-Batran S.E., Hartmann J.T., Hofheinz R., Homann N., Rethwisch V., Probst S., et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2008, 19:1882-1887.
37. Oishi T., Kigawa J., Fujiwara K., Fujiwara M., Numa F., Aotani E., et al. A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer. Gynecol Oncol 2003, 90:421-424.
38. Mäenpää J., Leminen A. Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study. Cancer Chemother Pharmacol 2009, 64:297-300.